Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication attempts to improve sexual desire, increase the number of satisfying sexual events, and decrease the distress associated with low sexual desire. The most common side effects are dizziness, sleepiness, nausea, difficulty falling asleep or staying asleep and dry mouth.
Flibanserin molecular structure diagram from the DrugsPRO substance library.
Also known as: 1-(2-(4-[3-(trifluormethyl)phenyl]piperazine-1-yl)ethyl)-1,3-dihydro-2 H- benzimidazole-2-one
Classification
Chemical: Medicine
Chemical: Piperazine
Effects
Stimulation
Nausea
Increased Heart Rate
Insomnia
Headache
Pupil Dilation
Talkativeness
Alertness Enhancement
Euphoria
Anxiety
Wakefulness
Mood Lift
Light Sensitivity
Dehydration
Appetite Suppression
Visual Distortion
Open Eye Visuals
Patterning
Routes of Administration
No route information available yet.
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Flibanserin - DrugsPRO průvodce látkou
Flibanserin: Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication attempts to improve sexual desire, increase the number of satisfying sexual events, and decrease the distress as
